异基因造血干细胞移植后序贯阿伐替尼治疗系统性肥大细胞增多症伴RUNX1-RUNX1T1阳性急性髓系白血病2例并文献复习

Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review

系统性肥大细胞增多症(SM)伴RUNX1-RUNX1T1阳性急性髓系白血病(AML)是一种较为罕见的髓系肿瘤, 目前尚无标准的治疗方案, 河南省肿瘤医院异基因造血干细胞移植(allo-HSCT)序贯阿伐替尼治疗2例SM伴RUNX1-RUNX1T1阳性AML患者, 骨髓中肥大细胞消失, C-KIT突变和RUNX1-RUNX1T1融合基因持续阴性。提示allo-HSCT后序贯阿伐替尼可作为SM伴RUNX1-RUNX1T1阳性AML患者的有效治疗手段。

Systemic mastocytosis(SM)with RUNX1-RUNX1T1 positive acute myeloid leukemia(AML)is a rare myeloid tumor with no standard treatment.Two cases of SM patients with RUNX1-RUNX1T1 positive AML treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation(allo-HSCT)were reported in Henan Cancer Hospital.Mast cell in bone marrow disappeared,C-KIT mutation and RUNX1-RUNX1T1 fusion gene remained negative.Allo-HSCT sequential avapritinib is an effective treatment for SM patients with RUNX1-RUNX1T1 positive AML.